Drug Trial Radar · NCT00244140
Ultravist: Safety and Efficacy in Computed Tomography of Head and Body
Last checked: Nov 20, 2026Latest source record: Feb 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
435
Actual
Start
Oct 2005
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study involving the use of a contrast agent called Ultravist Injection. Ultravist, the study drug, is used to improve the pictures obtained using computed tomography (CT). Ultravist acts like a dye to make CT pictures brighter and easier to read. In the case of this study, it will be injected into a vein in the patient's arm; from there, it travels through the blood stream and to the areas to be examined. CT scans will then be taken of the patient's head and/or body as ordered by his/her physician. Phase IIIb Study to Document the Safety and Efficacy of Ultravist 370 mg I/ml, When Administered Intravenously, in Volumes up to 162.2 ml, for Clinically Indicated Contrast Enhanced Computed Tomography (CECT) of the Head and/or Body
Conditions
- Computed Tomography
- Diagnostic Imaging
Interventions
Iopromide 370 mg I/mLDrug
Iopromide (Ultravist 370 mg I/mL) administered intravenously
Iopromide 300 mg I/mLDrug
Iopromide (Ultravist 300 mg I/mL) administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Quality of Visualization of the Contrast-Enhanced Computed Tomography (CECT) Images, Based on the Blinded Readers' Assessment.Time frame: post administration assessment of study images
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Miami, Florida
Site not named
Tallahassee, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Evanston, Illinois
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
New York, New York
Site not named
Stony Brook, New York
Site not named
Cleveland, Ohio
Site not named
Danville, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Bogotá, Colombia
Site not named
Medellín, Antioquia, Colombia
Site not named
Mumbai-400026, India
Site not named
Tamil Nadu, India
Site not named
Seoul, South Korea
Site not named
Seoul, Seoul Teugbyeolsi, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.